Amgen

PARSABIV

Manufacturer:

Amgen

Parsabiv HCPCS:

J0606

HCPCS Code Descriptor:

Injection, etelcalcetide, 0.1 mg

Category:

J Code

Parsabiv NDCs:

55513-0740-10, 55513-0741-10, 55513-0741-01, 55513-0740-01, 55513-0742-10, 55513-0742-01

Primary Type:

Unclassified

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Parsabiv CPT Codes:

Potential CPT administration codes for Parsabiv can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Parsabiv:

PARSABIV is an Unclassified drug manufactured by Amgen and administered via the Intravenous route of administration. The J Code: J0606 is aligned to the drug PARSABIV.

Parsabiv is a medication indicated for the treatment of secondary hyperparathyroidism, or sHPT. Parsabiv is approved for adult patients with sHPT with chronic kidney disease, who are also on hemodialysis. Parsabiv is thought to work by interacting with the body's parathyroid glands and reducing the amount of parathyroid hormone released by the body. With less parathyroid hormone present in the body, a patient's bones may release less phosphorus and calcium. Parsabiv is given intravenously and should not be given to patients with low calcium levels.

ACCESS PRICING AND MORE BY REGISTERING

J0606 Added Date:

January 1, 2018

J0606 Effective Date:

January 1, 2018

J0606 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Parsabiv billing and coding information.
Parsabiv patient assistance information can be found through Amgen’s Amgen Safety Net Foundation at the URL: http://www.amgensafetynetfoundation.com
PARSABIV prescribing information can be found at the link below:
Information regarding PARSABIV’s side effects can be found at MedlinePlus